Light-to-moderate ethanol feeding augments AMPK-α phosphorylation and attenuates SREBP-1 expression in the liver of rats

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 2, 2013, Pages 342-351

  Nammi, Srinivas ^a,b   Roufogalis, Basil D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN CLEAVAGE ACTIVATING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FOOD INTAKE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BODY WEIGHT; ETHANOL; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE; MEMBRANE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84890192213     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3788x     Document Type: Article

References (53)

1. Procopiou M, Philippe J. The metabolic syndrome and type 2 diabetes: epidemiological figures and country specificities. Cerebrovasc Dis, 2005; 20: 2-8.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004; 27: 1047-1053.
3. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med, 2006; 23: 469-480.
4. Bray GA, Bellanger T. Epidemiology, trends and morbidities of obesity and the metabolic syndrome. Endocrine, 2006: 29: 109-117.
5. Kahn SE, Hull RL, Utzchneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006; 444: 840-6.
6. Kao WHL, Puddey IB, Boland LL, Watson RL, Brancati FL. Alcohol consumption and the risk of type 2 diabetes: Atherosclerosis risk in communities study. Am J Epidemiol, 2001; 154: 748-57.
7. Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism. J Gastroenterol Hepatol, 2006; 21: S56-S60.
8. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol, 2004; 3: 9-19.
9. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol, 2006; 290: G852-G858.
10. Becker U, Deis A, Sorenson TI, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr P, Jensen G. Prediction of risk of liver damage by alcohol intake, sex and age: A prospective population study. Hepatology, 1996; 23: 1025-1029.
11. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Croce L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. The dionysos study group. Gut, 1997; 41: 845-850.
12. Savolainen VT, Leisto K, Mannikko A, Penttila A, Karhunen PJ. Alcohol consumption and alcoholic liver disease: Evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res, 1993; 17: 1112-1117.
13. Brenner DA. Moderate drinking: effects on the heart and liver. Gastroenerology, 2000; 119: 1399-1401.
14. Camargo CA, Hennekens C, Gaziano MJ, Glynn RJ, Manson JE, Stampfer MJ. Prospective study of moderate alcohol consumption and mortality in US male physicians. Arch Intern Med, 1997; 157: 79-85.
15. Doll R, Peto R, Hall E, Wheatley K, Gray R. Mortality in relation to consumption of alcohol: 13 years' observation on male British doctors. Br Med J, 1994; 309: 911-918.
16. Duffy JC. Alcohol consumption and all-cause mortality. Int J Epidemiol, 1995; 24: 100-105.
17. De Groot LC, Zock PL. Moderate alcohol intake and mortality. Nutr Rev, 1998, 56: 25-26.
18. Hoffmeister H, Schelp FP, Mensink GB, Dietz E, Bohning D. The relationship between alcohol consumption, health indicators and mortality in the German population. Int J Epidemiol, 1999; 28: 1066-1072.
19. Bell RA, Mayer-Davis EJ, Martin MA, D'Agostino RB Jr, Haffner SM. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors. The insulin resistance and atherosclerosis study. Diabetes Care, 2000; 23: 1630-1636.
20. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Campbell LV. Moderate alcohol consumption, estrogen replacement therapy, and physiological activity are associated with increased insulin sensitivity: Is abdominal adiposity the mediator? Diabetes Care, 2003; 26: 2734-40.
21. Wannamethee SG, Camargo Jr CA, Manson JE, Willett WC, Rimm EB. Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women. Arch Intern Med, 2003; 163: 1329-1336.
22. Berger K, Ajani UA, Kase CS, Gaziano JM, Buring JE, Glynn RJ, Hennekens CH. Light-tomoderate alcohol consumption and risk of stroke among US male physicians. N Engl J Med, 1999; 18: 1557-1564.
23. Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, Manson JE, Hennekens CH, Buring JE. Light-to-moderate alcohol consumption and mortality in the physician's health study enrollment cohort. J Am Coll Cardiol, 2000; 35: 96-105.
24. Diem P, Deplazes M, Fajfr R, Bearth A, Muller B, Christ ER, Teuscher A. Effects of alcohol consumption on mortality in patients with type 2 diabetes mellitus. Diabetologia, 2003; 46: 1581-1585.
25. Solomon CG, Hu FB, Stampfer MJ, Colditz GA, Speizer FE, Rimm EB, Willett WC, Manson JE. Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. Circulation, 2000; 102: 494-499.
26. Beulens JW, Rimm EB, Ascherio A, Spiegelman D, Hendriks HF, Mukamal KJ. Alcohol consumption and risk for coronary heart disease among men with hypertension. Ann Intern Med, 2007; 146: 10-19.
27. Malinski MK, Sesso HD, Lopex-Jimenez F, Buring JE, Gaziano JM. Alcohol consumption and cardiovascular disease mortality in hypertensive men. Arch Intern Med, 2004; 164: 623-628.
28. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Prior alcohol consumption and mortality following acute myocardial infarction. J Am Med Assoc, 2001; 285: 1965-1970.
29. Muntwyler J, Hennekens CH, Buring JE, Gaziano JM. Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet, 1998; 352: 1882-1885.
30. Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med, 2005; 352: 245-253.
31. Zuccala G, Onder G, Pedone C, Cesari M, Landi F, Bernabei R, Cocchi A. Dose-related impact of alcohol consumption on cognitive function in advanced age: results of a multicenter survey. Alcohol Clin Exp Res, 2001; 25: 1743-1748.
32. Standridge JB, Zylstra RG, Adams SM. Alcohol consumption: an overview of benefits and risks. South Med J, 2004; 97: 664-672.
33. La Vecchia C, Negri E, Franceschi S, D'Avanzo B. Moderate beer consumption and the risk of colorectal cancer. Nutr Cancer, 1993; 19: 303-306.
34. Cotrim HP, Freitas LA, Alves E, Almeida A, May DS, Caldwell S. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol, 2009; 21: 969-972.
35. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Pridictors of nonalcoholic steatohepatitis and liver fibrosis in the serverely obese. Gastroenterology, 2001; 121: 91-100.
36. Hara A, Radin NS. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem, 1978; 90: 420.
37. Garcia-Villafranca J, Guillen A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMPactivated protein kinase in rat liver. Biochemie, 2008; 90: 460-466.
38. You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol, 2004; 34: 39-43.
39. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology, 2004; 127: 1798-1808.
40. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci, 2004; 29: 18-24.
41. Winder WW. Energy sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol, 2001; 91: 1017-1028.
42. Hardie DG. Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase. Biochem Biophys Acta, 1992; 1123: 231-238.
43. Kim KH. Regulation of mammalian acetylcoenzyme A carboxylase. Annu Rev Nutr, 1997; 17: 77-99.
44. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem, 1997; 244: 1-14.
45. Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol, 1999; 276: E1-E18.
46. Saha AK, Ruderman NB. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem, 2003; 253: 65-70.
47. Feng L, Gao L, Guan Q, Hou X, Wan Q, Wang X, Zhao J. Long-term moderate ethanol consumption restores insulin sensitivity in high-fat-fed rats by increasing GLUT4 in the adipose tissue by AMPK activation. J Endocrinol, 2008; 199: 95-104.
48. Fromenty B, Vadrot N, Massart J, Turlin B, Barri- Ova N, Letteron P, Fautrel A, Robin MA. Chronic Ethanol Consumption Lessens the Gain of Body Weight, Liver Triglycerides, and Diabetes in Obese ob/ob mice. J Pharmacol Exp Ther, 2009; 331: 23-34
49. Lieber CS. Alcohol and the liver: 1994 update. Gastroenterology, 1994; 106: 1085-1105.
50. McCarty. Toward practical prevention of type 2 diabetes. Med Hypotheses, 2000; 54: 786-793.
51. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest, 2002; 109: 1125-1131.
52. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med, 2000; 6: 998-1003.
53. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk- Melody J, Wu M, Ventre J, Doebber T, Fujji N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001; 108: 1167-1174.